tJûn17 LSA Regulatory Affairs & Market Access Chat Podcast Por Stephen F. Amato PhD MBA RAC arte de portada

tJûn17 LSA Regulatory Affairs & Market Access Chat

tJûn17 LSA Regulatory Affairs & Market Access Chat

De: Stephen F. Amato PhD MBA RAC
Escúchala gratis

This tJûn17 Life Sciences Advisors (LSA) podcast series will explore current topics in the field(s) of global regulatory affairs, reimbursement, pricing....in short, all things market access. The podcast will feature news, guest speakers that serve as experts in the field of global healthcare, including industry professionals, regulators, patient advocacy groups, and other stakeholders. Tune in to get the latest and greatest information about relevant topics in global healthcare and market access.© 2023 tJûn17 LSA Regulatory Affairs & Market Access Chat Ciencia Política Economía Educación Gestión Gestión y Liderazgo Política y Gobierno
Episodios
  • Novel Technologies Used to Address and Reduce Global COVID-19 Incidence - June 2021

    Novel Technologies Used to Address and Reduce Global COVID-19 Incidence - June 2021
    Aug 12 2021
    1 h y 7 m
  • Controversy & Dialogue Surrounding the Commercialization of Aduhelm

    Controversy & Dialogue Surrounding the Commercialization of Aduhelm
    Aug 12 2021
    1 h y 6 m
  • tJûn17 Life Sciences Advisors Regulatory Affairs and Market Access Chat - Preview Podcast

    tJûn17 Life Sciences Advisors Regulatory Affairs and Market Access Chat - Preview Podcast
    Aug 2 2021

    This tJûn17 Life Sciences Advisors (LSA) podcast series will explore current topics in the field(s) of global regulatory affairs, reimbursement, pricing....in short, all things market access. The podcast will feature news, guest speakers that serve as experts in the field of global healthcare, including industry professionals, regulators, patient advocacy groups, and other stakeholders. Tune in to get the latest and greatest information about relevant topics in global healthcare and market access.   For full website see tJûn17 Life Sciences Advisors
    Más Menos
    13 m
Todavía no hay opiniones